Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
2678 articles with Eli Lilly and Company
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment
10/9/2020
Largest Real-World Study of Patient-Reported Outcomes in People with Migraine Shows the Use of Novel CGRP Monoclonal Antibody Class May Improve Migraine
-
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China
10/9/2020
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company ("Lilly", NYSE: LLY),
-
Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries
10/8/2020
Eli Lilly and Company and the Bill & Melinda Gates Foundation, as part of the COVID-19 Therapeutics Accelerator, have entered into an agreement to facilitate access to future Lilly therapeutic antibodies under development for the prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus, to benefit low- and middle-income countries.
-
Indy Racial Equity Pledge Launches to Drive Accountability, Action and Progress on Racial Equity
10/8/2020
Local coalition launches pledge and website, calling on more Central Indiana organizations to sign on, make commitments and track progress publicly
-
Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen
10/8/2020
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir
-
Lilly Confirms Date and Conference Call for Third-Quarter 2020 Financial Results Announcement
10/8/2020
Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2020 financial results on Tuesday, October 27, 2020 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time . Investor
-
Results from multiple Phase III trials show consistent improvements in pain relief and physical function.
-
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
10/7/2020
Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients.
-
Lilly and Dexcom team up on new program to help improve diabetes management
10/7/2020
Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring, highlighting the benefits of using each
-
Eli Lilly is seeking Emergency Use Authorization for its antibody therapy, LY-CoV555, for the treatment of high-risk patients with recently diagnosed mild-to-moderate coronavirus disease 2019 (COVID-19).
-
REYVOW® (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study
10/6/2020
Patients on REYVOW had 3.8-7.2 Times Greater Odds of Achieving Pain Freedom at 2 Hours Versus Placebo in At Least 2 out of 3 Attacks, Resulting in Significant Therapeutic Gains of 10-20%
-
Care Access Research Partners on Revolutionary Mobile Clinical Trial for COVID-19 Treatment
10/1/2020
Care Access Research, the leader in rapid development and management of high-performing clinical research sites, announced that it is collaborating with global healthcare leader Eli Lilly and Company.
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
Trulicity® (dulaglutide) to reduce the risk of non-fatal stroke in adults with type 2 diabetes
9/22/2020
- On September 11, 2020, Health Canada approved Trulicity® (dulaglutide) to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease, as an adjunct to diet, exercise, and standard of care therapy. This decision makes Eli Lilly and Company’s Trulicity the first and only GLP1 receptor agonist (RA) approved to provide a cardiovascular benefit in people w
-
Clinical Catch-Up: September 14-18
9/21/2020
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies. -
Verzenio® Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer
9/20/2020
Verzenio in combination with endocrine therapy is the only CDK4 & 6 inhibitor to demonstrate a statistically significant improvement in invasive disease-free survival (IDFS) in early breast cancer
-
CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
9/18/2020
Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
-
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
9/17/2020
Eli Lilly and Company and Amgen announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly's potential COVID-19 therapies.
-
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
9/16/2020
Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points